+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Enzyme Inhibitor Market by Product Type (Ace Inhibitors, Hmg-Coa Reductase Inhibitors, Polymerase Inhibitors), Indication (Cardiovascular, Infectious Diseases, Metabolic Disorders), Route Of Administration, Distribution Channel, End User - Global Forecast 2025-2030- Product Image
Enzyme Inhibitor Market by Product Type (Ace Inhibitors, Hmg-Coa Reductase Inhibitors, Polymerase Inhibitors), Indication (Cardiovascular, Infectious Diseases, Metabolic Disorders), Route Of Administration, Distribution Channel, End User - Global Forecast 2025-2030- Product Image
Sale

Enzyme Inhibitor Market by Product Type (Ace Inhibitors, Hmg-Coa Reductase Inhibitors, Polymerase Inhibitors), Indication (Cardiovascular, Infectious Diseases, Metabolic Disorders), Route Of Administration, Distribution Channel, End User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 186 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6015291
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Enzyme inhibitors are transforming modern therapeutics, with rapid innovation driving new treatment solutions across diverse disease areas. This market continues to evolve, shaped by breakthrough research, advanced technologies, and sophisticated regulatory strategies, positioning it as a key growth sector for senior decision makers in biopharmaceuticals.

Market Snapshot: Enzyme Inhibitor Market

The enzyme inhibitor market grew from USD 2.25 billion in 2024 to USD 2.42 billion in 2025. It is expected to continue growing at a CAGR of 7.40%, reaching USD 3.46 billion by 2030. This sustained momentum is underpinned by robust demand for targeted therapies, continued investments in precision medicine, and adaptation to dynamic regulatory conditions. Companies are increasingly leveraging structural biology and high-throughput screening to advance more effective and differentiated therapeutic candidates.

Scope & Segmentation

  • Product Types: ACE inhibitors (captopril, enalapril, lisinopril), HMG-CoA reductase inhibitors (atorvastatin, rosuvastatin, simvastatin), polymerase inhibitors (non-nucleoside, nucleoside analog), protease inhibitors (hepatitis C, HIV), and tyrosine kinase inhibitors (Bcr-Abl, EGFR – first, second, third generation, VEGFR).
  • Therapeutic Indications: Cardiovascular (heart failure, hypertension, myocardial infarction), infectious diseases (hepatitis C, HIV), metabolic disorders (diabetes, obesity), neurology (Alzheimer’s, Parkinson’s), oncology (breast, colorectal, lung – small cell and non-small cell, prostate).
  • Route of Administration: Intravenous, oral (capsule, oral solution, tablet).
  • Distribution Channels: Hospital pharmacies, online pharmacies, retail pharmacies.
  • End Users: Clinics, homecare, hospitals.
  • Regional Coverage: Americas (US – California, Texas, New York, etc.; Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (UK, Germany, France, Russia, UAE, South Africa, etc.), Asia-Pacific (China, India, Japan, Australia, South Korea, Southeast Asia, etc.).
  • Key Technologies: High-throughput screening, structural biology, artificial intelligence, computational modeling, machine learning for predictive drug design.
  • Leading Companies: F. Hoffmann-La Roche Ltd, Pfizer Inc., Novartis International AG, Merck & Co., Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline plc, AbbVie Inc., Gilead Sciences, Inc.

Key Takeaways for Senior Decision Makers

  • Precision medicine and biomarker-driven strategies are reshaping discovery and development, enabling highly targeted patient therapies and improving risk-benefit profiles.
  • Artificial intelligence and machine learning accelerate candidate identification and optimization, helping reduce timeframes and R&D costs.
  • Combination therapies, including enzyme inhibitors with immunotherapies and biologics, are gaining traction due to enhanced clinical outcomes and broader applicability across complex diseases.
  • Regional dynamics and reimbursement requirements drive the need for adaptive market access and localization strategies, particularly in emerging and diverse healthcare systems.
  • Strategic alliances, licensing, and joint ventures are increasingly vital in bringing niche innovations to market and expanding geographic reach, strengthening industry collaboration and resilience.
  • Competitive advantage hinges on successful pipeline differentiation and leveraging external partnerships to augment in-house capabilities and accelerate time to market.

Tariff Impact: Navigating 2025 Supply Chain Challenges

New US tariffs introduced in 2025 directly affect enzyme inhibitor supply chains, with increased import duties on key raw materials and APIs. Organizations are reassessing supplier relationships, considering onshoring options, and prioritizing supply chain resilience to buffer operational costs and mitigate potential disruptions. Realignment of R&D and procurement strategies is apparent, as companies strive to balance innovation with operational efficiency and continuity.

Methodology & Data Sources

This report utilized a rigorous multi-method approach, combining comprehensive secondary research, in-depth interviews with industry leaders and clinical experts, and quantitative market analysis. Triangulation across data sources was employed to validate findings and assess the impact of regulations, tariff changes, and technological advancements on growth trajectories.

Why This Report Matters

  • Provides actionable insights for investment prioritization and efficient market entry.
  • Enables risk mitigation through in-depth analysis of regional and policy-driven disruptions.
  • Equips stakeholders with the strategic context to pursue productive collaborations and optimize product lifecycle management.

Conclusion

The enzyme inhibitor market is evolving rapidly, offering new commercial prospects and requiring adaptive, forward-thinking strategies. In-depth sector intelligence enables leaders to identify growth opportunities, meet global challenges, and inform data-driven decision making effectively.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Leveraging CRISPR-based screening to identify novel enzyme inhibitor targets in oncology
5.2. Development of dual-action enzyme inhibitors combining kinase and protease inhibition for improved efficacy
5.3. Integration of artificial intelligence in design and optimization of enzyme inhibitor lead compounds
5.4. Adoption of reversible covalent binding strategies to enhance selectivity and safety profiles of inhibitors
5.5. Expanding enzyme inhibitor applications in metabolic disease treatment through gut microbiome modulation research
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Enzyme Inhibitor Market, by Product Type
8.1. Introduction
8.2. Ace Inhibitors
8.2.1. Captopril
8.2.2. Enalapril
8.2.3. Lisinopril
8.3. Hmg-Coa Reductase Inhibitors
8.3.1. Atorvastatin
8.3.2. Rosuvastatin
8.3.3. Simvastatin
8.4. Polymerase Inhibitors
8.4.1. Non-Nucleoside Polymerase Inhibitors
8.4.2. Nucleoside Analog Polymerase Inhibitors
8.5. Protease Inhibitors
8.5.1. Hepatitis C Protease Inhibitors
8.5.2. Hiv Protease Inhibitors
8.6. Tyrosine Kinase Inhibitors
8.6.1. Bcr-Abl Inhibitors
8.6.2. Egfr Inhibitors
8.6.2.1. First Generation Inhibitors
8.6.2.2. Second Generation Inhibitors
8.6.2.3. Third Generation Inhibitors
8.6.3. Vegfr Inhibitors
9. Enzyme Inhibitor Market, by Indication
9.1. Introduction
9.2. Cardiovascular
9.2.1. Heart Failure
9.2.2. Hypertension
9.2.3. Myocardial Infarction
9.3. Infectious Diseases
9.3.1. Hepatitis C
9.3.2. HIV
9.4. Metabolic Disorders
9.4.1. Diabetes
9.4.2. Obesity
9.5. Neurology
9.5.1. Alzheimers Disease
9.5.2. Parkinsons Disease
9.6. Oncology
9.6.1. Breast Cancer
9.6.2. Colorectal Cancer
9.6.3. Lung Cancer
9.6.3.1. Non-Small Cell Lung Cancer
9.6.3.2. Small Cell Lung Cancer
9.6.4. Prostate Cancer
10. Enzyme Inhibitor Market, by Route Of Administration
10.1. Introduction
10.2. Intravenous
10.3. Oral
10.3.1. Capsule
10.3.2. Oral Solution
10.3.3. Tablet
11. Enzyme Inhibitor Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacies
11.3. Online Pharmacies
11.4. Retail Pharmacies
12. Enzyme Inhibitor Market, by End User
12.1. Introduction
12.2. Clinics
12.3. Homecare
12.4. Hospitals
13. Americas Enzyme Inhibitor Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Enzyme Inhibitor Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Enzyme Inhibitor Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. F. Hoffmann-La Roche Ltd
16.3.2. Pfizer Inc.
16.3.3. Novartis International AG
16.3.4. Merck & Co., Inc.
16.3.5. Sanofi S.A.
16.3.6. Bristol-Myers Squibb Company
16.3.7. AstraZeneca PLC
16.3.8. GlaxoSmithKline plc
16.3.9. AbbVie Inc.
16.3.10. Gilead Sciences, Inc.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. ENZYME INHIBITOR MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL ENZYME INHIBITOR MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS ENZYME INHIBITOR MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS ENZYME INHIBITOR MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES ENZYME INHIBITOR MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES ENZYME INHIBITOR MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ENZYME INHIBITOR MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ENZYME INHIBITOR MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC ENZYME INHIBITOR MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC ENZYME INHIBITOR MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ENZYME INHIBITOR MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. ENZYME INHIBITOR MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. ENZYME INHIBITOR MARKET: RESEARCHAI
FIGURE 26. ENZYME INHIBITOR MARKET: RESEARCHSTATISTICS
FIGURE 27. ENZYME INHIBITOR MARKET: RESEARCHCONTACTS
FIGURE 28. ENZYME INHIBITOR MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. ENZYME INHIBITOR MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL ENZYME INHIBITOR MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL ENZYME INHIBITOR MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY ACE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY ACE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY CAPTOPRIL, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY CAPTOPRIL, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY ENALAPRIL, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY ENALAPRIL, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY LISINOPRIL, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY LISINOPRIL, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY ACE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY ACE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY HMG-COA REDUCTASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY HMG-COA REDUCTASE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY ATORVASTATIN, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY ATORVASTATIN, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY ROSUVASTATIN, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY ROSUVASTATIN, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY SIMVASTATIN, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY SIMVASTATIN, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY HMG-COA REDUCTASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY HMG-COA REDUCTASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY POLYMERASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY POLYMERASE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY NON-NUCLEOSIDE POLYMERASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY NON-NUCLEOSIDE POLYMERASE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY NUCLEOSIDE ANALOG POLYMERASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY NUCLEOSIDE ANALOG POLYMERASE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY POLYMERASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY POLYMERASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY PROTEASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY PROTEASE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY HEPATITIS C PROTEASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY HEPATITIS C PROTEASE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY HIV PROTEASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY HIV PROTEASE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY PROTEASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY PROTEASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY BCR-ABL INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY BCR-ABL INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY EGFR INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY EGFR INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY FIRST GENERATION INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY FIRST GENERATION INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY SECOND GENERATION INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY SECOND GENERATION INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY THIRD GENERATION INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY THIRD GENERATION INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY EGFR INHIBITORS, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY EGFR INHIBITORS, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY VEGFR INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY VEGFR INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY HEART FAILURE, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY HEART FAILURE, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY HYPERTENSION, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY HYPERTENSION, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY MYOCARDIAL INFARCTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY MYOCARDIAL INFARCTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY CARDIOVASCULAR, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY CARDIOVASCULAR, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY HEPATITIS C, BY REGION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY HEPATITIS C, BY REGION, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY HIV, BY REGION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY HIV, BY REGION, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY DIABETES, BY REGION, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY DIABETES, BY REGION, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY OBESITY, BY REGION, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY OBESITY, BY REGION, 2025-2030 (USD MILLION)
TABLE 91. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY METABOLIC DISORDERS, 2018-2024 (USD MILLION)
TABLE 92. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY METABOLIC DISORDERS, 2025-2030 (USD MILLION)
TABLE 93. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2024 (USD MILLION)
TABLE 94. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY NEUROLOGY, BY REGION, 2025-2030 (USD MILLION)
TABLE 95. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY ALZHEIMERS DISEASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 96. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY ALZHEIMERS DISEASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 97. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY PARKINSONS DISEASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 98. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY PARKINSONS DISEASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 99. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY NEUROLOGY, 2018-2024 (USD MILLION)
TABLE 100. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY NEUROLOGY, 2025-2030 (USD MILLION)
TABLE 101. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
TABLE 102. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2030 (USD MILLION)
TABLE 103. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 104. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY BREAST CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 105. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 106. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 107. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 108. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY LUNG CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 109. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 110. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 111. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY SMALL CELL LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 112. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY SMALL CELL LUNG CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 113. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 114. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 115. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 116. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 117. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 118. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 119. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 120. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 121. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 122. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 123. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 124. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 125. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY CAPSULE, BY REGION, 2018-2024 (USD MILLION)
TABLE 126. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY CAPSULE, BY REGION, 2025-2030 (USD MILLION)
TABLE 127. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY ORAL SOLUTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 128. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY ORAL SOLUTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 129. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY TABLET, BY REGION, 2018-2024 (USD MILLION)
TABLE 130. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY TABLET, BY REGION, 2025-2030 (USD MILLION)
TABLE 131. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 132. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 133. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 134. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 135. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 136. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 137. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 138. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 139. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 140. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 141. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 142. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 143. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 144. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 145. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY HOMECARE, BY REGION, 2018-2024 (USD MILLION)
TABLE 146. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY HOMECARE, BY REGION, 2025-2030 (USD MILLION)
TABLE 147. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 148. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 149. AMERICAS ENZYME INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 150. AMERICAS ENZYME INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 151. AMERICAS ENZYME INHIBITOR MARKET SIZE, BY ACE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 152. AMERICAS ENZYME INHIBITOR MARKET SIZE, BY ACE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 153. AMERICAS ENZYME INHIBITOR MARKET SIZE, BY HMG-COA REDUCTASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 154. AMERICAS ENZYME INHIBITOR MARKET SIZE, BY HMG-COA REDUCTASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 155. AMERICAS ENZYME INHIBITOR MARKET SIZE, BY POLYMERASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 156. AMERICAS ENZYME INHIBITOR MARKET SIZE, BY POLYMERASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 157. AMERICAS ENZYME INHIBITOR MARKET SIZE, BY PROTEASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 158. AMERICAS ENZYME INHIBITOR MARKET SIZE, BY PROTEASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 159. AMERICAS ENZYME INHIBITOR MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 160. AMERICAS ENZYME INHIBITOR MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 161. AMERICAS ENZYME INHIBITOR MARKET SIZE, BY EGFR INHIBITORS, 2018-2024 (USD MILLION)
TABLE 162. AMERICAS ENZYME INHIBITOR MARKET SIZE, BY EGFR INHIBITORS, 2025-2030 (USD MILLION)
TABLE 163. AMERICAS ENZYME INHIBITOR MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 164. AMERICAS ENZYME INHIBITOR MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 165. AMERICAS ENZYME INHIBITOR MARKET SIZE, BY CARDIOVASCULAR, 2018-2024 (USD MILLION)
TABLE 166. AMERICAS ENZYME INHIBITOR MARKET SIZE, BY CARDIOVASCULAR, 2025-2030 (USD MILLION)
TABLE 167. AMERICAS ENZYME INHIBITOR MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
TABLE 168. AMERICAS ENZYME INHIBITOR MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
TABLE 169. AMERICAS ENZYME INHIBITOR MARKET SIZE, BY METABOLIC DISORDERS, 2018-2024 (USD MILLION)
TABLE 170. AMERICAS ENZYME INHIBITOR MARKET SIZE, BY METABOLIC DISORDERS, 2025-2030 (USD MILLION)
TABLE 171. AMERICAS ENZYME INHIBITOR MARKET SIZE, BY NEUROLOGY, 2018-2024 (USD MILLION)
TABLE 172. AMERICAS ENZYME INHIBITOR MARKET SIZE, BY NEUROLOGY, 2025-2030 (USD MILLION)
TABLE 173. AMERICAS ENZYME INHIBITOR MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 174. AMERICAS ENZYME INHIBITOR MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 175. AMERICAS ENZYME INHIBITOR MARKET SIZE, BY LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 176. AMERICAS ENZYME INHIBITOR MARKET SIZE, BY LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 177. AMERICAS ENZYME INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 178. AMERICAS ENZYME INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 179. AMERICAS ENZYME INHIBITOR MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 180. AMERICAS ENZYME INHIBITOR MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 181. AMERICAS ENZYME INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 182. AMERICAS ENZYME INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 183. AMERICAS ENZYME INHIBITOR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 184. AMERICAS ENZYME INHIBITOR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 185. AMERICAS ENZYME INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 186. AMERICAS ENZYME INHIBITOR MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 187. UNITED STATES ENZYME INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 188. UNITED STATES ENZYME INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 189. UNITED STATES ENZYME INHIBITOR MARKET SIZE, BY ACE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 190. UNITED STATES ENZYME INHIBITOR MARKET SIZE, BY ACE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 191. UNITED STATES ENZYME INHIBITOR MARKET SIZE, BY HMG-COA REDUCTASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 192. UNITED STATES ENZYME INHIBITOR MARKET SIZE, BY HMG-COA REDUCTASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 193. UNITED STATES ENZYME INHIBITOR MARKET SIZE, BY POLYMERASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 194. UNITED STATES ENZYME INHIBITOR MARKET SIZE, BY POLYMERASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 195. UNITED STATES ENZYME INHIBITOR MARKET SIZE, BY PROTEASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 196. UNITED STATES ENZYME INHIBITOR MARKET SIZE, BY PROTEASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 197. UNITED STATES ENZYME INHIBITOR MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 198. UNITED STATES ENZYME INHIBITOR MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 199. UNITED STATES ENZYME INHIBITOR MARKET SIZE, BY EGFR INHIBITORS, 2018-2024 (USD MILLION)
TABLE 200. UNITED STATES ENZYME INHIBITOR MARKET SIZE, BY EGFR INHIBITORS, 2025-2030 (USD MILLION)
TABLE 201. UNITED STATES ENZYME INHIBITOR MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 202. UNITED STATES ENZYME INHIBITOR MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 203. UNITED STATES ENZYME INHIBITOR MARKET SIZE, BY CARDIOVASCULAR, 2018-2024 (USD MILLION)
TABLE 204. UNITED STATES ENZYME INHIBITOR MARKET SIZE, BY CARDIOVASCULAR, 2025-2030 (USD MILLION)
TABLE 205. UNITED STATES ENZYME INHIBITOR MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
TABLE 206. UNITED STATES ENZYME INHIBITOR MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
TABLE 207. UNITED STATES ENZYME INHIBITOR MARKET SIZE, BY METABOLIC DISORDERS, 2018-2024 (USD MILLION)
TABLE 208. UNITED STATES ENZYME INHIBITOR MARKET SIZE, BY METABOLIC DISORDERS, 2025-2030 (USD MILLION)
TABLE 209. UNITED STATES ENZYME INHIBITOR MARKET SIZE, BY NEUROLOGY, 2018-2024 (USD MILLION)
TABLE 210. UNITED STATES ENZYME INHIBITOR MARKET SIZE, BY NEUROLOGY, 2025-2030 (USD MILLION)
TABLE 211. UNITED STATES ENZYME INHIBITOR MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 212. UNITED STATES ENZYME INHIBITOR MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 213. UNITED STATES ENZYME INHIBITOR MARKET SIZE, BY LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 214. UNITED STATES ENZYME INHIBITOR MARKET SIZE, BY LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 215. UNITED STATES ENZYME INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 216. UNITED STATES ENZYME INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 217. UNITED STATES ENZYME INHIBITOR MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 218. UNITED STATES ENZYME INHIBITOR MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 219. UNITED STATES ENZYME INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 220. UNITED STATES ENZYME INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 221. UNITED STATES ENZYME INHIBITOR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 222. UNITED STATES ENZYME INHIBITOR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 223. UNITED STATES ENZYME INHIBITOR MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 224. UNITED STATES ENZYME INHIBITOR MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 225. CANADA ENZYME INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 226. CANADA ENZYME INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 227. CANADA ENZYME INHIBITOR MARKET SIZE, BY ACE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 228. CANADA ENZYME INHIBITOR MARKET SIZE, BY ACE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 229. CANADA ENZYME INHIBITOR MARKET SIZE, BY HMG-COA REDUCTASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 230. CANADA ENZYME INHIBITOR MARKET SIZE, BY HMG-COA REDUCTASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 231. CANADA ENZYME INHIBITOR MARKET SIZE, BY POLYMERASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 232. CANADA ENZYME INHIBITOR MARKET SIZE, BY POLYMERASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 233. CANADA ENZYME INHIBITOR MARKET SIZE, BY PROTEASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 234. CANADA ENZYME INHIBITOR MARKET SIZE, BY PROTEASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 235. CANADA ENZYME INHIBITOR MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 236. CANADA ENZYME INHIBITOR MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 237. CANADA ENZYME INHIBITOR MARKET SIZE, BY EGFR INHIBITORS, 2018-2024 (USD MILLION)
TABLE 238. CANADA ENZYME INHIBITOR MARKET SIZE, BY EGFR INHIBITORS, 2025-2030 (USD MILLION)
TABLE 239. CANADA ENZYME INHIBITOR MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 240. CANADA ENZYME INHIBITOR MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 241. CANADA ENZYME INHIBITOR MARKET SIZE, BY CARDIOVASCULAR, 2018-2024 (USD MILLION)
TABLE 242. CANADA ENZYME INHIBITOR MARKET SIZE, BY CARDIOVASCULAR, 2025-2030 (USD MILLION)
TABLE 243. CANADA ENZYME INHIBITOR MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
TABLE 244. CANADA ENZYME INHIBITOR MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
TABLE 245. CANADA ENZYME INHIBITOR MARKET SIZE, BY METABOLIC DISORDERS, 2018-2024 (USD MILLION)
TABLE 246. CANADA ENZYME INHIBITOR MARKET SIZE, BY METABOLIC DISORDERS, 2025-2030 (USD MILLION)
TABLE 247. CANADA ENZYME INHIBITOR MARKET SIZE, BY NEUROLOGY, 2018-2024 (USD MILLION)
TABLE 248. CANADA ENZYME INHIBITOR MARKET SIZE, BY NEUROLOGY, 2025-2030 (USD MILLION)
TABLE 249. CANADA ENZYME INHIBITOR MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 250. CANADA ENZYME INHIBITOR MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 251. CANADA ENZYME INHIBITOR MARKET SIZE, BY LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 252. CANADA ENZYME INHIBITOR MARKET SIZE, BY LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 253. CANADA ENZYME INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 254. CANADA ENZYME INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 255. CANADA ENZYME INHIBITOR MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 256. CANADA ENZYME INHIBITOR MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 257. CANADA ENZYME INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 258. CANADA ENZYME INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 259. CANADA ENZYME INHIBITOR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 260. CANADA ENZYME INHIBITOR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 261. MEXICO ENZYME INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 262. MEXICO ENZYME INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 263. MEXICO ENZYME INHIBITOR MARKET SIZE, BY ACE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 264. MEXICO ENZYME INHIBITOR MARKET SIZE, BY ACE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 265. MEXICO ENZYME INHIBITOR MARKET SIZE, BY HMG-COA REDUCTASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 266. MEXICO ENZYME INHIBITOR MARKET SIZE, BY HMG-COA REDUCTASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 267. MEXICO ENZYME INHIBITOR MARKET SIZE, BY POLYMERASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 268. MEXICO ENZYME INHIBITOR MARKET SIZE, BY POLYMERASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 269. MEXICO ENZYME INHIBITOR MARKET SIZE, BY PROTEASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 270. MEXICO ENZYME INHIBITOR MARKET SIZE, BY PROTEASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 271. MEXICO ENZYME INHIBITOR MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 272. MEXICO ENZYME INHIBITOR MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 273. MEXICO ENZYME INHIBITOR MARKET SIZE, BY EGFR INHIBITORS, 2018-2024 (USD MILLION)
TABLE 274. MEXICO ENZYME INHIBITOR MARKET SIZE, BY EGFR INHIBITORS, 2025-2030 (USD MILLION)
TABLE 275. MEXICO ENZYME INHIBITOR MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 276. MEXICO ENZYME INHIBITOR MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 277. MEXICO ENZYME INHIBITOR MARKET SIZE, BY CARDIOVASCULAR, 2018-2024 (USD MILLION)
TABLE 278. MEXICO ENZYME INHIBITOR MARKET SIZE, BY CARDIOVASCULAR, 2025-2030 (USD MILLION)
TABLE 279. MEXICO ENZYME INHIBITOR MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
TABLE 280. MEXICO ENZYME INHIBITOR MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
TABLE 281. MEXICO ENZYME INHIBITOR MARKET SIZE, BY METABOLIC DISORDERS, 2018-2024 (USD MILLION)
TABLE 282. MEXICO ENZYME INHIBITOR MARKET SIZE, BY METABOLIC DISORDERS, 2025-2030 (USD MILLION)
TABLE 283. MEXICO ENZYME INHIBITOR MARKET SIZE, BY NEUROLOGY, 2018-2024 (USD MILLION)
TABLE 284. MEXICO ENZYME INHIBITOR MARKET SIZE, BY NEUROLOGY, 2025-2030 (USD MILLION)
TABLE 285. MEXICO ENZYME INHIBITOR MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 286. MEXICO ENZYME INHIBITOR MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 287. MEXICO ENZYME INHIBITOR MARKET SIZE, BY LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 288. MEXICO ENZYME INHIBITOR MARKET SIZE, BY LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 289. MEXICO ENZYME INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 290. MEXICO ENZYME INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 291. MEXICO ENZYME INHIBITOR MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 292. MEXICO ENZYME INHIBITOR MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 293. MEXICO ENZYME INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 294. MEXICO ENZYME INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 295. MEXICO ENZYME INHIBITOR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 296. MEXICO ENZYME INHIBITOR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 297. BRAZIL ENZYME INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 298. BRAZIL ENZYME INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 299. BRAZIL ENZYME INHIBITOR MARKET SIZE, BY ACE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 300. BRAZIL ENZYME INHIBITOR MARKET SIZE, BY ACE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 301. BRAZIL ENZYME INHIBITOR MARKET SIZE, BY HMG-COA REDUCTASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 302. BRAZIL ENZYME INHIBITOR MARKET SIZE, BY HMG-COA REDUCTASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 303. BRAZIL ENZYME INHIBITOR MARKET SIZE, BY POLYMERASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 304. BRAZIL ENZYME INHIBITOR MARKET SIZE, BY POLYMERASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 305. BRAZIL ENZYME INHIBITOR MARKET SIZE, BY PROTEASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 306. BRAZIL ENZYME INHIBITOR MARKET SIZE, BY PROTEASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 307. BRAZIL ENZYME INHIBITOR MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 308. BRAZIL ENZYME INHIBITOR MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 309. BRAZIL ENZYME INHIBITOR MARKET SIZE, BY EGFR INHIBITORS, 2018-2024 (USD MILLION)
TABLE 310. BRAZIL ENZYME INHIBITOR MARKET SIZE, BY EGFR INHIBITORS, 2025-2030 (USD MILLION)
TABLE 311. BRAZIL ENZYME INHIBITOR MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 312. BRAZIL ENZYME INHIBITOR MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 313. BRAZIL ENZYME INHIBITOR MARKET SIZE, BY CARDIOVASCULAR, 2018-2024 (USD MILLION)
TABLE 314. BRAZIL ENZYME INHIBITOR MARKET SIZE, BY CARDIOVASCULAR, 2025-2030 (USD MILLION)
TABLE 315. BRAZIL ENZYME INHIBITOR MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
TABLE 316. BRAZIL ENZYME INHIBITOR MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
TABLE 317. BRAZIL ENZYME INHIBITOR MARKET SIZE, BY METABOLIC DISORDERS, 2018-2024 (USD MILLION)
TABLE 318. BRAZIL ENZYME INHIBITOR MARKET SIZE, BY METABOLIC DISORDERS, 2025-2030 (USD MILLION)
TABLE 319. BRAZIL ENZYME INHIBITOR MARKET SIZE, BY NEUROLOGY, 2018-2024 (USD MILLION)
TABLE 320. BRAZIL ENZYME INHIBITOR MARKET SIZE, BY NEUROLOGY, 2025-2030 (USD MILLION)
TABLE 321. BRAZIL ENZYME INHIBITOR MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 322. BRAZIL ENZYME INHIBITOR MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 323. BRAZIL ENZYME INHIBITOR MARKET SIZE, BY LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 324. BRAZIL ENZYME INHIBITOR MARKET SIZE, BY LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 325. BRAZIL ENZYME INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 326. BRAZIL ENZYME INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 327. BRAZIL ENZYME INHIBITOR MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 328. BRAZIL ENZYME INHIBITOR MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 329. BRAZIL ENZYME INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 330. BRAZIL ENZYME INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 331. BRAZIL ENZYME INHIBITOR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 332. BRAZIL ENZYME INHIBITOR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 333. ARGENTINA ENZYME INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 334. ARGENTINA ENZYME INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 335. ARGENTINA ENZYME INHIBITOR MARKET SIZE, BY ACE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 336. ARGENTINA ENZYME INHIBITOR MARKET SIZE, BY ACE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 337. ARGENTINA ENZYME INHIBITOR MARKET SIZE, BY HMG-COA REDUCTASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 338. ARGENTINA ENZYME INHIBITOR MARKET SIZE, BY HMG-COA REDUCTASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 339. ARGENTINA ENZYME INHIBITOR MARKET SIZE, BY POLYMERASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 340. ARGENTINA ENZYME INHIBITOR MARKET SIZE, BY POLYMERASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE

Samples

Loading
LOADING...

Companies Mentioned

The major companies profiled in this Enzyme Inhibitor market report include:
  • F. Hoffmann-La Roche Ltd
  • Pfizer Inc.
  • Novartis International AG
  • Merck & Co., Inc.
  • Sanofi S.A.
  • Bristol-Myers Squibb Company
  • AstraZeneca PLC
  • GlaxoSmithKline plc
  • AbbVie Inc.
  • Gilead Sciences, Inc.

Table Information

Report AttributeDetails
No. of Pages186
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 2.42 Billion
Forecasted Market Value ( USD ) by 2030 $ 3.46 Billion
Compound Annual Growth Rate7.4%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Ribonucleotide Reductase Inhibitors - Pipeline Insight, 2025 - Product Image

Ribonucleotide Reductase Inhibitors - Pipeline Insight, 2025

  • Drug Pipelines
  • 60 Pages
  • Global
From
Diagnostic Enzymes Market Size, Share & Trends Analysis Report by Type (Taq Polymerase, MMLV RT, HIV RT), Application (Diabetes, Oncology, Cardiology), Product, End-use, Region, and Segment Forecasts, 2025-2030 - Product Image

Diagnostic Enzymes Market Size, Share & Trends Analysis Report by Type (Taq Polymerase, MMLV RT, HIV RT), Application (Diabetes, Oncology, Cardiology), Product, End-use, Region, and Segment Forecasts, 2025-2030

  • Report
  • 120 Pages
  • Global
From
Poly ADP-Ribose Polymerase (PARP) Inhibitor Market Report 2025 - Product Image

Poly ADP-Ribose Polymerase (PARP) Inhibitor Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Poly ADP-Ribose Polymerase (PARP) Inhibitors - Global Strategic Business Report - Product Image

Poly ADP-Ribose Polymerase (PARP) Inhibitors - Global Strategic Business Report

  • Report
  • 284 Pages
  • Global
From
Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Global Market Report 2025 - Product Image

Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Global Market Report 2025

  • Report
  • 175 Pages
  • Global
From

About the Enzyme Inhibitor Market

The Enzyme Inhibitor market is a segment of the Pharmaceuticals industry that focuses on the development and production of drugs that inhibit the activity of enzymes. Enzyme inhibitors are used to treat a variety of diseases, including cancer, cardiovascular disease, and metabolic disorders. They are also used to treat infections, such as HIV and hepatitis. Enzyme inhibitors are typically administered orally or intravenously, and can be used in combination with other drugs. The Enzyme Inhibitor market is highly competitive, with many companies vying for market share. Companies in the market are focused on developing new drugs and improving existing ones, as well as expanding their product portfolios. Companies are also investing in research and development to create more effective enzyme inhibitors. Some of the major companies in the Enzyme Inhibitor market include Pfizer, Merck, Novartis, AstraZeneca, and Bristol-Myers Squibb. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.